SMP vs RIRS for Symptomatic Lower Pole Renal Calculi of 10-20 mm Size: a Randomized Controlled Trial

Super-Mini Percutaneous Nephrolithotomy (SMP) Versus Retrograde Intrarenal Surgery (RIRS) for Symptomatic Lower Pole Renal Calculi of 10-20 mm Size: a Randomized Controlled Trial (IAU-01)

Shock wave lithotripsy (SWL) is recommended for kidney stones < 20 mm. However, the stone clearance of lower pole calculi after SWL is limited, thus leading to an extended indication for mini-percutaneous nephrolithotripsy (PCNL) even for stones between 10 and 20 mm in many centers. This trend is further promoted by introduction of super-mini PCNL (SMP), which is postulated to be less invasive compared to mini-PCNL due to the miniaturized instruments. However, this issue remains controversial.

On the other hand, improvements in endoscopy technology have made retrograde stone removal more attractive. This has led to an increasing use of RIRS as a primary treatment although it is recommended only as 2nd-line option by current guidelines. However, the treatment of symptomatic lower pole calculi is a challenge for RIRS because of lower clearance rates.

The purpose of this study is to evaluate the efficacy and safety of SMP and RIRS for the treatment for symptomatic lower pole calculi renal calculi measuring 10-20 mm.

Study Overview

Detailed Description

To evaluate the efficacy and safety of SMP and RIRS for the treatment for symptomatic lower pole calculi renal calculi measuring 10-20 mm.Investigators will do a multi-centers international randomized controlled trial(RCT),and investigators plan to perform this study in 10 hospitals,which are the First Affiliated Hospital of Guangzhou Medical University of China, Department of Urology, Renmin Hospital, Wuhan University of China, Shenzhen People's Hospital of China, The Second Affiliated Hospital of Zhengzhou University of China, The Second Affiliated Hospital of Harbin Medical University of China, Zhujiang Hospital of Southern Medical University of China, Jiangsu Province hospital, The First Affiliated Hospital With Nanjing Medical University of China, Zhejiang provincial people's hospital of china, Dr. Lutfi Kirdar Training and Research Hospital of Turkey and Global Rainbow Healthcare of India respectively.

Investigators plan to beginning their study at August in 2015 and end at July in 2017.One hundred and sixty patients with symptomatic lower pole calculi renal calculi measuring 10-20 mm will be enrolled in this study. By simple random sampling technique, patients will be assigned to two 80-patient groups.All the patients will be diagnosed definitely before operations with non-contrast CT.Patients with positive preoperative urine culture should be treated with suitable antibiotics based on the culture sensitivity result for at least 72h before SMP/RIRS. Patients who have negative urine culture should receive a single dose of broad spectrum antibiotic prophylaxis just prior to the procedure.

Surgical technique

SMP

All the biochemistry tests and preoperative preparations are referenced to the mini-PCNL. Under general anesthesia a 6 French(Fr).Open end ureteral catheter is first inserted in to the relevant ureter. Patient is then turned into prone position and the desired calyx is punctured under fluoroscopic or sonographic guidance. Nephrostomy tract dilation is carried out using fascial dilators up to 12-14 Fr. as indicated. Corresponding size of suction-evacuation sheath was placed. The sheath is connected to the specimen collection bottle and the bottle then onto the aspirator. A rubber cap with a center aperture was placed at the proximal end of the sheath. The negative pressure aspirator was adjusted to a setting of 150-200 mm Hg. The miniature endoscope is inserted into the sheath through the cap. Stone is visualized and lithotripsy is performed using either Holmium-yttrium aluminum garnet(YAG) laser or pneumatic lithotripsy. At the end of procedure fluoroscopic images are obtained to assess stone clearance status. Double J ureteral stent is placed only in the presence of ureteral inflammatory polyp; evidence of ureteropelvic obstruction; presence of significant pyelocalyceal blood clots following lithotripsy; significant residual stones. Indications for nephrostomy tube placement included: significant residual stone fragments which would require a second look procedure; significant pyelocalyceal blood clots or bleeding after lithotripsy (because the nephrostomy tube could tamponade the access tract and drain the urine and clots).

RIRS

The patient is placed in the lithotomy position, Cystoscopy and retrograde pyelogram were preformed, and a 0.035'' flexible tip guidewire is placed into the renal pelvis. A 12 Fr/ 14 Fr ureteral access sheath (UAS) is advanced into the proximal ureter over the guidewire, and a P5 or P6 Olympus flexible ureteroscope is passed through the UAS. The stones are fragmented using a 200um holmium laser fibre at a 8-25 weeks energy setting. Some fragments are removed using a stone basket for stone analysis, and the remaining stone fragments smaller than 2 mm were left for spontaneous passage. A 5 Fr or 6Fr pigtail stent is placed at the conclusion of the procedure. Double J stents were removed post-operative 2 weeks.

Data collection

Data for the 2 groups-demographic characteristics,hemoglobin(HB) decrease, postoperative pain, duration of postoperative, hospital stay, complications (modified Clavien system), stone clearance (SFR after day 1 and final SFR) and the need for auxiliary treatment are compared.

Mean study endpoint: The primary endpoint was the SFR at 3-months after surgery.

Secondary endpoint: Complications, duration of postoperative and hospital stay. re-SMP, ureteroscopy and SWL are considered as auxiliary treatments. Demographic characteristics include age, sex, BMI, stone size and location, etc…

The stone size is defined as the maximum diameter as determined by CT scans.

Degree of hydronephrosis are assigned as follow: none (no calyx or pelvic dilation), mild (pelvic dilatation alone), moderate (mild calyx dilation), or severe (severe calyx dilation or calyx dilation accompanied by renal parenchyma atrophy).

Definition of operation time:

For SMP: recorded from the time of the first percutaneous renal puncture to the completion of the stone removal.

For RIRS: recorded from insertion of an endoscope into the urethra to the completion of stent placement.

Hospital stay are rounded to the nearest whole day and calculated from the day of surgery to the day of discharge.

Postoperative pain (visual analogue scale(VAS), use of analgesics) and Postoperative comfort scores (Bruggrmann comfort scale,BCS) will be recorded.

The rate of hemoglobin decrease is assessed by comparing the preoperative Hb level with 24-hour postoperative Hb level.

SFR is assessed by KUB and ultrasound at 1-day after operation.

Non-contrast CT is obtained for all patients at 3 month after the operation to evaluate the final SFR, allowing time for the spontaneous passage of stone fragments.

Stone-free status are defined as either the absence of any residual stone fragments or the presence of clinically insignificant residual stone fragments in the kidney which were defined as ≦ 3mm, asymptomatic, non-obstructive and non-infectious stone particles.

If the procedure is considered as successful, the pigtail stent is removed as outpatient after 2 weeks. Follow-up including non-contrast CT will be generally scheduled in 3 month.

Bleeding severity is judged by the treating physician, and transfusions are administered according to local practice guideline.

Complications of all patients are recorded according to modified Clavien classification system.

Study Type

Interventional

Enrollment (Actual)

160

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Guangdong
      • Guangzhou, Guangdong, China, 510230
        • Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 68 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Age 18 to 70 years
  2. Normal renal function
  3. Anesthesia rating(ASA) score 1 and 2
  4. Absence of congenital abnormalities
  5. Symptomatic lower pole calculi and diameter 10-20 mm

Exclusion Criteria:

  1. Patients with solitary kidney
  2. Patients with congenital anomalies, e.g. ectopic kidney, polycystic horseshoe, or mal-rotated kidney
  3. Patients who underwent transplant or urinary diversion
  4. Uncorrected coagulopathy and active urinary tract infection(UTI)
  5. Patient undergoing any other surgical procedure during the same admission. (e.g. ureteroscopy)
  6. If patients undergoing RIRS/SMP have purulent urine, we will place D-J stent (for RIRS) or nephrostomy tube (for SMP) and postpone the procedure and excluded the patients from the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Group 1
Patients in Group 1 undergo Super-Mini Percutaneous Nephrolithotomy
Patients undergo Super-Mini Percutaneous Nephrolithotomy
Other: Group 2
Patients in Group 2 undergo Retrograde Intrarenal Surgery
Patients undergo Retrograde Intrarenal Surgery

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stone free rate (SFR)
Time Frame: The primary endpoint was the SFR at 3-months after surgery.
Stone-free status are defined as either the absence of any residual stone fragments or the presence of clinically insignificant residual stone fragments in the kidney which were defined as ≦ 3mm, asymptomatic, non-obstructive and non-infectious stone particles.
The primary endpoint was the SFR at 3-months after surgery.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Perioperative complications
Time Frame: intraoperatively or ≤ 3 month postoperatively
Complication is defined as any adverse event occurred intraoperatively or ≤3 month postoperatively.
intraoperatively or ≤ 3 month postoperatively
Operation time
Time Frame: intraoperatively
The operating time for SMP was recorded from the time of the first percutaneous renal puncture to wound closure;For RIRS,The operating time was recorded from insertion of an endoscope into the urethra to the completion of stent placement.
intraoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2015

Primary Completion (Actual)

July 31, 2017

Study Completion (Actual)

July 31, 2017

Study Registration Dates

First Submitted

August 3, 2015

First Submitted That Met QC Criteria

August 6, 2015

First Posted (Estimate)

August 11, 2015

Study Record Updates

Last Update Posted (Actual)

April 1, 2020

Last Update Submitted That Met QC Criteria

March 30, 2020

Last Verified

March 1, 2020

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Renal Calculi

Clinical Trials on Retrograde Intrarenal Surgery

3
Subscribe